Comparison of baseline characteristics between MMRd, p53abn, and MMRd-p53abn
| Characteristics | Molecular class | P value | Multiple comparisons p value | |||
| MMRd (n=99) | p53abn (n=73) | MMRd-p53abn (n=28) | MMRd vs p53abn vs MMRd-p53abn | MMRd vs MMRd-p53abn | p53abn vs MMRd-p53abn | |
| Clinical and pathologic characteristics | ||||||
| Age at surgery (years), mean (SD) | 61.3 (10.2) | 66.7 (11.0) | 63.0 (10.7) | <0.001 | 1.000 | 0.353 |
| BMI (kg/m2), mean (SD) | 27.6 (7.8) | 28.0 (6.4) | 27.8 (5.5) | 0.51 | – | – |
| Early vs advanced-stage, n (%) | 0.002 | 0.220 | 0.203 | |||
| Early (I–II) | 72 (72.7) | 34 (46.6) | 17 (60.7) | |||
| Advanced | 27 (27.3) | 39 (53.4) | 11 (39.3) | |||
| Endometrioid vs other, n (%) | <0.001 | 0.006 | 0.001 | |||
| Endometrioid | 97 (98.0) | 36 (50.0) | 23 (85.2) | |||
| Non-endometrioid | 2 (2.0) | 36 (50.0) | 4 (14.8) | |||
| Missing | 0 | 1 | 1 | |||
| Grade, n (%) | <0.001 | 0.001 | 0.139 | |||
| G1–2 | 77 (77.8) | 21 (28.8) | 12 (44.4) | |||
| G3 | 22 (22.2) | 52 (71.2) | 15 (55.6) | |||
| Missing | 0 | 0 | 1 | |||
| Myometrial invasion, n (%) | 0.58 | – | – | |||
| None | 14 (14.1) | 10 (14.1) | 4 (14.8) | |||
| <50 | 52 (52.5) | 31 (43.7) | 16 (59.3) | |||
| ≥50 | 33 (33.3) | 30 (42.3) | 7 (25.9) | |||
| Unknown | 0 | 2 | 1 | |||
| LVSI, n (%) | 0.87 | – | – | |||
| Absent or focal | 81 (82.7) | 54 (79.4) | 22 (81.5) | |||
| Diffuse | 17 (17.4) | 14 (20.6) | 5 (18.5) | |||
| Missing | 1 | 5 | 1 | |||
| Lymph node metastases, n (%) | 0.79 | – | – | |||
| Negative | 76 (80.0) | 40 (75.5) | 20 (74.1) | |||
| ITC | 4 (4.2) | 1 (1.9) | 1 (3.7) | |||
| Micro/macro | 15 (15.8) | 12 (22.6) | 6 (22.2) | |||
| Missing/unknown | 4 | 20 | 1 | |||
| Risk classification*, n (%) | <0.001 | 0.149 | 0.058 | |||
| Low | 43 (43.4) | 10 (13.7) | 7 (25.0) | |||
| Intermediate | 20 (20.2) | 8 (11.0) | 8 (28.6) | |||
| High-intermediate | 14 (14.1) | 8 (11.0) | 3 (10.7) | |||
| High | 21 (21.2) | 30 (41.1) | 8 (28.6) | |||
| Advanced/metastatic | 1 (1.0) | 17 (23.3) | 2 (7.1) | |||
| Molecular characteristics | ||||||
| MMR proteins deficiency | ||||||
| MLH1, n (%) | – | 0.010 | ||||
| Loss of expression | 70 (71.4) | – | 12 (44.4) | |||
| Equivocal | 3 (3.1) | – | 0 | |||
| Normal expression | 25 (25.5) | – | 15 (55.6) | |||
| Missing | 1 | 1 | ||||
| PMS2, n (%) | – | <0.001 | ||||
| Loss of expression | 76 (78.4) | – | 12 (44.4) | |||
| Equivocal | 3 (3.1) | – | 0 | |||
| Normal expression | 18 (18.6) | – | 15 (55.6) | |||
| Missing | 2 | 1 | ||||
| MSH2, n (%) | – | 0.690 | ||||
| Loss of expression | 10 (10.2) | – | 4 (14.8) | |||
| Equivocal | 2 (2.0) | – | 1 (3.7) | |||
| Normal expression | 86 (87.8) | – | 22 (81.45) | |||
| Missing | 1 | 1 | ||||
| MSH6, n (%) | – | <0.001 | ||||
| Loss of expression | 19 (19.4) | – | 15 (55.6) | |||
| Equivocal | 3 (3.1) | – | 1 (3.7) | |||
| Normal expression | 76 (77.6) | – | 11 (40.7) | |||
| Missing | 1 | 1 | ||||
| MSI, n (%) | – | 0.560 | ||||
| MSI | 83 (88.3) | – | 24 (92.3) | |||
| MSS | 11 (11.7) | – | 2 (7.7) | |||
| Missing | 5 | 2 | ||||
| p53 IHC, n (%) | – | 0.005 | ||||
| Aberrant | – | 64 (91.4) | 14 (63.6) | |||
| Subclonal | – | 2 (2.9) | 4 (18.2) | |||
| Wild type expression | – | 4 (5.7) | 4 (18.2) | |||
| Missing | 3 | 6 | ||||
| TP53 NGS, n (%) | – | 0.361 | ||||
| Pathogenic | – | 67 (91.8) | 24 (85.7) | |||
| Wild type | – | 6 (8.2)† | 4 (14.3) | |||
*ESGO/ESTRO/ESP guidelines, 2020 – molecular classification unknown.
†A case of VUS was considered as wild-type.
BMI, body mass index; ESGO, European Society of Gynaecological Oncology; ESP, European Society of Pathology; ESTRO, European Society for Radiotherapy and Oncology; IHC, immunohistochemistry; ITC, isolated tumor cells; LVSI, lymphovascular space invasion; MMRd, mismatch repair deficient; MSI, microsatellite instability; MSS, microsatellite stable; NGS, next-generation sequencing; p53abn, p53 abnormal; SD, standard deviation; VUS, variant of uncertain significance.